Abstract
The strategy in the treatment of metastatic renal cell carcinoma (MRCC) is based on prognostic factors for survival. General performance status, delay from the diagnosis of primary tumor to occurrence of metastases, number of metastatic sites or site of metastases (lung, liver) and biological changes such as hemoglobin value, calcium value, and sedimentation rate are reported as the most predictive factors for survival. The first line of treatment in MRCC is immunotherapy for the majority of patients. Disagreement remains regarding the choice of immunotherapy: interleukin-2 (IL-2) and/or interferon alpha; and the mode of administration of IL-2: intravenous or subcutaneous route. Major therapeutic changes are coming with new drugs directed against new targets. Bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF) has been approved in second-line treatment. Other compounds are under investigation such as drugs targeting the EGF and Ras pathways.
Keywords: biphosphonates, immunotherapy, anti-angiogenic therapy, metastatic sites, nephrectomy, fluorouracile, cardiac toxicity, antitumoral activity, interferon (ifn)
Current Cancer Therapy Reviews
Title: Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma
Volume: 1 Issue: 2
Author(s): Alain Ravaud, Marie-Sarah Dilhuydy, Aimery Huchet, Stephane Pedeboscq and Jean-Philippe Maire
Affiliation:
Keywords: biphosphonates, immunotherapy, anti-angiogenic therapy, metastatic sites, nephrectomy, fluorouracile, cardiac toxicity, antitumoral activity, interferon (ifn)
Abstract: The strategy in the treatment of metastatic renal cell carcinoma (MRCC) is based on prognostic factors for survival. General performance status, delay from the diagnosis of primary tumor to occurrence of metastases, number of metastatic sites or site of metastases (lung, liver) and biological changes such as hemoglobin value, calcium value, and sedimentation rate are reported as the most predictive factors for survival. The first line of treatment in MRCC is immunotherapy for the majority of patients. Disagreement remains regarding the choice of immunotherapy: interleukin-2 (IL-2) and/or interferon alpha; and the mode of administration of IL-2: intravenous or subcutaneous route. Major therapeutic changes are coming with new drugs directed against new targets. Bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF) has been approved in second-line treatment. Other compounds are under investigation such as drugs targeting the EGF and Ras pathways.
Export Options
About this article
Cite this article as:
Ravaud Alain, Dilhuydy Marie-Sarah, Huchet Aimery, Pedeboscq Stephane and Maire Jean-Philippe, Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma, Current Cancer Therapy Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573394054021709
DOI https://dx.doi.org/10.2174/1573394054021709 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Neonatal Germ Cell Tumors
Current Pediatric Reviews The HGF-Met Signaling Axis: Emerging Themes and Targets of Inhibition
Current Protein & Peptide Science Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119
Current Radiopharmaceuticals Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry Diagnosis of Alterations of Serum Calcium Metabolism
Medicinal Chemistry Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation
Current Medicinal Chemistry Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics The Contrasting Roles of NKT Cells in Tumor Immunity
Current Molecular Medicine Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets A Nuclear Receptor-Mediated Xenobiotic Response and Its Implication in Drug Metabolism and Host Protection
Current Drug Metabolism